FinTechFunding

Zelira Therapeutics: Launches Zenivol in Australia

  • Zelira Therapeutics (ZLD) has launched its proprietary cannabinoid medicine, Zenivol, in Australia
  • The company has received approval from the Therapeutic Goods Administration’s (TGA) Special Access Scheme to launch the treatment
  • Zenivol is for patients with chronic insomnia and will be available through Zelira’s distribution partner, Health House
  • This announcement follows a successful clinical trial conducted by the University of Western Australia
  • Zelira is on track to launch five new products across global markets in 2020
  • Company shares are up 10 per cent on the market this morning, trading for 6.6 cents per share
Previous article
Saunders International: Awarded $26M defence contract
Next article
Elevations Credit Union: Selects Temenos Infinity
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

FinTech

Italy Fines Revolut €1.15M for Regulatory Violations

Revolut faces penalties due to non-compliance with Italian financial regulations.Highlights: Italy fines Revolut €1.15 million for regulatory breaches.The...
FinTech

DeFi Platform Drift Suspends Withdrawals After Crypto Hack

Drift takes precautionary measures following security breach affecting user funds.Highlights: Drift has suspended all deposits and withdrawals after...
FinTech

Cross River Bank Raises $50 Million to Accelerate Growth

The funding will enhance Cross River Bank's financial technology services.Highlights: Cross River Bank has raised $50 million in...
FinTech

Kulipa Secures $62M to Enhance Stablecoin Card Issuing Infrastructure

Funding aims to strengthen cryptocurrency card services in the growing fintech market.Highlights: Kulipa raises $62M to enhance its...